Wednesday, May 21, 2025 5/21/2025

Validation and qualification of an ex vivo human cardiac tissue-based assay for the assessment of the potential cardiotoxicity of pharmaceutical compounds

Award Number: R44TR001133
ORGANIZATION: NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

Group Awards By:

View Award Description

Validation and qualification of an ex vivo human cardiac tissue-based assay for the assessment of the potential cardiotoxicity of pharmaceutical compounds - PROJECT SUMMARY Drug-induced cardiac toxicity and adverse events remain a major challenge for both industry as well as regulators. The current strategies for early identification of these potential liabilities in the drug discovery and development process involves a combination of in vitro assays, animal models and an extensive ECG-based cardiac repolarization study which is conducted on human subjects during Phase 2 clinical trial. These latter studies are known as “Thorough QT” studies (TQT) since they have specifically focused on drug-related changes in the QT interval, a biomarker for cardiac repolarization and the induction of pro-arrhythmic cardiac activity. While these strategies have contributed in the identification of potentially dangerous pro-arrhythmic molecules, it is also becoming apparent that this approach is amenable to significant improvements. Recently, the leadership at the Division of Cardiovascular and Renal Products of the FDA Center for Drug Evaluation and Research has facilitated a number of initiatives aimed at soliciting the development and validation of novel experimental models for assessing cardiac safety of new drugs. As explicitly stated by the regulators, the goal is “to replace the TQT clinical studies with one or more pre-clinical assays, by July 2015” (Dr. Norman Stockbridge, CSRC-HESI-FDA Meeting, July 24, 2013, Silver Spring, MD). Species differences create insurmountable limitations for all approached based on animal models. In addition, newer strategies relying on cardiomyocytes artificially derived from stem cells or iPS cells do not faithfully replicate all the physiological features of native adult human cardiomyocytes and do not model the effects of aging and comorbidities. AnaBios has recently developed a novel ex-vivo human heart-based drug safety evaluation platform, which is currently undergoing formal Biomarker Qualification at the FDA. The technology relies upon the utilization of viable human donor hearts in the laboratory for conducting ex-vivo measurements of cardiac action potentials to determine the arrhythmogenicity of new drugs. This approach was initially validated in Phase I using a set of 5 reference compounds tested in blinded fashion. We demonstrated the ability of this human ex- vivo assay to correctly discriminate pro-arrhythmic from non-pro-arrhythmic drugs. This new approach provides the next of kin to a human clinical cardiac study, but avoids the risks related to drug exposure in humans in the clinic, as well as the high costs and extended timelines which come with the clinical studies. The present Phase II proposal will fully leverage our ex-vivo human heart methods by further validating and refining the arrhythmogenicity model and by advancing the platform to a commercialization-ready stage that will permit service of a large number of drug safety evaluations. By providing researchers with the relevant human based safety data, we anticipate the services resulting from this Phase II project will transform cardiac drug safety assessment.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2019 ( Subtotal = $0 )
2019	2017	ANABIOS CORPORATION	3030 BUNKER HILL ST STE 312	SAN DIEGO	CA	92109	SAN DIEGO	USA	National Center for Advancing Translational Sciences	000	3	11/28/2018	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2017 ( Subtotal = $549,693 )
2017	2017	ANABIOS CORPORATION	3030 BUNKER HILL ST STE 312	SAN DIEGO	CA	92109	SAN DIEGO	USA	National Center for Advancing Translational Sciences	000	3	6/23/2017	NON-COMPETING CONTINUATION	$549,693
														Subtotal = $549,693

Issue Date FY: 2016 ( Subtotal = $945,014 )
2016	2016	ANABIOS CORPORATION	3030 BUNKER HILL ST STE 312	SAN DIEGO	CA	92109	SAN DIEGO	USA	National Center for Advancing Translational Sciences	000	2	7/7/2016	COMPETING CONTINUATION	$945,014
														Subtotal = $945,014

Grand Total All Awards = $1,494,707

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Validation and qualification of an ex vivo human cardiac tissue-based assay for the assessment of the potential cardiotoxicity of pharmaceutical compounds

Award Number: R44TR001133

ORGANIZATION: NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer